Recall Enforment Report D-0145-2024

Recall Details

Drug Recall Enforcement Report Class I voluntary initiated by Bayer Healthcare Pharmaceuticals Inc., originally initiated on 11-06-2023 for the product VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01 The product was recalled due to microbial contamination of non-sterile products: microbial contamination identified as penicillium brevicompactum observed during routine ongoing stability testing. The product was distributed nationwide and the recall is currently ongoing.

Field Name Field Value
Event ID 93391 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0145-2024 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Product was distributed to specialty pharmacies and distributors nationwide who may have further distributed the product. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01
Reason For Recall Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 192 bottles Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 12-06-2023
Recall Initiation Date 11-06-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Bayer Healthcare Pharmaceuticals Inc.
Code Info Lot# 2114228, EXP. 02/29/2024 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 50419-390-01; 50419-391-01; 50419-392-01; 50419-393-02; 50419-393-03
Status Ongoing

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
50419-390Vitrakvi LarotrectinibCapsuleOralBayer Healthcare Pharmaceuticals Inc.Human Prescription Drug
50419-391Vitrakvi LarotrectinibCapsuleOralBayer Healthcare Pharmaceuticals Inc.Human Prescription Drug
50419-392Vitrakvi LarotrectinibSolution, ConcentrateOropharyngealBayer Healthcare Pharmaceuticals Inc.Human Prescription Drug
50419-393Vitrakvi LarotrectinibSolution, ConcentrateOropharyngealBayer Healthcare Pharmaceuticals Inc.Human Prescription Drug